Skip to content
Microfluidic-based Vascular Network Bioprinting
Future Tech

Edited by Alex Surfaced·Healthcare·3 min read
Share:

Microfluidic-based Vascular Network Bioprinting is an advanced technique focused specifically on creating intricate, perfusable blood vessel networks within engineered tissues or organ constructs. This method uses microfluidic channels and specialized bioinks containing endothelial cells to precisely print and mature a hierarchical vascular tree, crucial for supplying oxygen and nutrients to larger engineered tissues. Researchers at Rice University, the University of Pennsylvania, and the Wyss Institute at Harvard University are pioneers in this challenging field. The technology is in advanced research, with successful demonstrations of perfusable microvessels and small vascularized tissue blocks. In February 2023, a team at Rice University successfully bioprinted a functional microvascular network within a hydrogel using a 'sugar templating' method, achieving stable perfusion for several weeks, published in *Nature Biomedical Engineering*. This aims to overcome the critical limitation of scale-up in tissue engineering, where constructs larger than a few hundred micrometers often fail due to lack of vascularization.

Signal trackedAdvanced ResearchSource: lewis.seas.harvard.edu

Editorial check

How this page is checked

Source:lewis.seas.harvard.edu

Source trail

lewis.seas.harvard.edu

External links are separated from Surfaced commentary.

Reader safety

Context before clicks

Product links and external services are not presented as guarantees.

Monetization

No affiliate flag

Ads and commerce links are kept distinct from editorial text.

Surfaced take

Why It Matters

The inability to create functional vascular networks is the primary hurdle preventing the engineering of large, complex organs like livers or kidneys, hindering solutions for millions suffering from organ failure. When successful, this technology would unlock the potential for truly functional, full-sized bioengineered organs, transforming transplant medicine and regenerative therapies for numerous diseases. Patients awaiting complex organ transplants and the entire field of tissue engineering win; current organ transplant infrastructure might need to adapt. Major technical challenges include maintaining long-term patency of printed vessels, achieving physiological blood flow dynamics, and seamlessly integrating bioprinted networks with host vasculature upon implantation. Widespread application in complex organ engineering is likely 15-25 years away, with simpler vascularized tissues potentially sooner. US academic institutions, particularly those with strong bioengineering departments, are leading this highly specialized race. A second-order consequence is the potential for new forms of advanced surgical repair where customized vascular networks are printed in situ to rapidly heal complex trauma or disease, far beyond current capabilities.

Development Stage

Early Research
Advanced Research
Prototype
Early Commercialization
Growth Phase

Enjoyed this? Get five picks like this every morning.

Free daily newsletter — zero spam, unsubscribe anytime.

Get the day's top tech discoveries delivered at 6 PM.

Free, source-linked, and easy to unsubscribe from.